Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A B Beasley

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Journal of the Medical Society of New Jersey|July 1, 1976
Following footstepsA I Sutnick, M E Hartman, A B Beasley
Circulation|June 1, 1978
Nonuniform cardiac sympathetic nerve discharge: mechanism for coronary occlusion and digitalis-induced arrhythmiaC M Lathers, G J Kelliher, J Roberts, et al.
Cardiovascular Research|March 1, 1979
Comparison of the arrhythmogenic effect of myocardial infarction in the cat and dogR D Reynolds, G J Kelliher, D M Ritchie, et al.
ESMO Open|November 23, 2023
Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapyA Abed, A B Beasley, A L Reid, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Journal of the Medical Society of New Jersey|July 1, 1976
Following footstepsA I Sutnick, M E Hartman, A B Beasley
Circulation|June 1, 1978
Nonuniform cardiac sympathetic nerve discharge: mechanism for coronary occlusion and digitalis-induced arrhythmiaC M Lathers, G J Kelliher, J Roberts, et al.
Cardiovascular Research|March 1, 1979
Comparison of the arrhythmogenic effect of myocardial infarction in the cat and dogR D Reynolds, G J Kelliher, D M Ritchie, et al.
ESMO Open|November 23, 2023
Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapyA Abed, A B Beasley, A L Reid, et al.
Pageof 1